Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
Vir Biotechnology (Nasdaq: VIR) will provide a corporate update and report its third-quarter financial results on November 3, 2022. These results cover the period ending September 30, 2022, and will be released after market close. Investors can access the update through the company’s website. Vir focuses on immunology and has a development pipeline targeting serious infectious diseases, including COVID-19 and hepatitis. The company combines immunologic insights with advanced technologies to enhance immune response.
- None.
- None.
SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
FAQ
When will Vir Biotechnology report its third quarter financial results?
What is the focus of Vir Biotechnology?
Where can I find the corporate update from Vir Biotechnology?
What is the stock symbol for Vir Biotechnology?
